ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos ETM-0-0-09176 10.3892/etm.2020.9176 Articles Helicobacter pylori is associated with weakened pulmonary function and reduced incidence of allergic conditions in patients with chronic cough HeMeng 1 * ZhengYuanyuan 2 * MaA'Huo 2 * ZhangChunyi 1 YuYuefang 1 WangHua 1 ChenYefeng 1 XiangMin 1 TaoKelong 3 ShenJuxin 1 Department of Respiratory Medicine, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Zhejiang University School of Medicine, Shaoxing, Zhejiang 312000, P.R. China Department of Gastroenterology, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Zhejiang University School of Medicine, Shaoxing, Zhejiang 312000, P.R. China Department of Gastrointestinal Surgery, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Zhejiang University School of Medicine, Shaoxing, Zhejiang 312000, P.R. China Correspondence to: Dr Kelong Tao, Department of Gastrointestinal Surgery, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Zhejiang University School of Medicine, 568 Zhongxing North Road, Shaoxing, Zhejiang 312000, P.R. China fykelong@163.com

Professor Juxin Shen, Department of Respiratory Medicine, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Zhejiang University School of Medicine, 568 Zhongxing North Road, Shaoxing, Zhejiang 312000, P.R. China sxrmsjx@126.com

*Contributed equally

 11 2020 03 09 2020 20 5 47 26 07 2019 10 06 2020 Copyright: © He et al. 2020 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The present study aimed to investigate the potential association between Helicobacter pylori (a H. pylori) positive state and chronic cough. A clinical observational study with systematic analysis was performed, including 278 patients with complaints of chronic cough and 148 healthy controls. a H. pylori positive state was present in 61.2% of the patients in the chronic cough group and 68.9% in the chronic refractory cough group, as opposed to 43.9% in the control group. There was a significant improvement in 65.5% of the patients with chronic refractory cough following successful a H. pylori eradication therapy. In addition, patients with chronic cough exposed to a H. pylori exhibited decreased pulmonary function with a decrease in forced expiratory volume in 1 sec by 84 ml, a decrease in the forced vital capacity by 53 ml and a decrease in maximal vital capacity by 46 ml. The difference was even more obvious in the chronic refractory cough group. The allergy status differed significantly according to age between a H. pylori-positive and -negative cases in the cough variant asthma and allergic cough groups. Among patients aged <40 years, a H. pylori-positive cases had a lower prevalence of atopy and lower total serum immunoglobin E levels compared with a H. pylori-negative cases. However, there was no significant association between a H. pylori status and C-reactive protein levels, erythrocyte sedimentation rate or eosinophil count in the peripheral blood. In conclusion, the present study demonstrated that a H. pylori infection may be a factor associated with chronic cough and it may be associated with a decline in pulmonary function and reduced incidence of allergic conditions. Thus, a H. pylori may represent a target for the treatment of chronic cough.

 Helicobacter pylori chronic cough chronic refractory cough cough variant asthma allergic cough lung function atopy immunoglobulin E hypersensitivity Introduction

Chronic cough (CC) is a common clinical condition that may disrupt the everyday activities of affected patients, including their work. The prevalence of CC among the adult population has been reported to range between 13 and 32% (1). By definition, CC is a cough lasting for >8 weeks in patients who have a normal chest radiograph, are not receiving therapy with angiotensin-converting enzyme inhibitors and have not been exposed to environmental irritants (1,2). According to the data reported in the literature, cough variant asthma (CVA), upper airway cough syndrome (UACS), allergic cough (AC), eosinophilic bronchitis (EB) and gastroesophageal reflux-related cough (GERC) are the major causes of CC, accounting for ~70-95% of the causes in Chinese patients (3,4). Certain patients may have more than one of these conditions. However, in a significant number of patients, the cause of the cough may remain elusive, or the cough may be refractory to treatment, despite extensive investigations and therapeutic trials. Unexplained chronic cough (UCC) is a major health concern that occurs in up to 5-10% of the Chinese population (5,6). Furthermore, although the aetiology may be identified in certain patients, there is no effective treatment method or there may be no treatment response, leading to persistent cough (7). Collectively, UCC and persistent cough with poor therapeutic response are referred to as chronic refractory cough (CRC), which occurs in up to 12-42% of cases (8).

Chronic persistent cough may interrupt patients' sleep, leading to exhaustion. Affected patients experience a marked decline in their quality of life. They frequently seek medical help at various hospitals throughout China, are repeatedly subjected to a variety of examinations and receive a number of different drugs, suffer from various adverse drug reactions and carry a heavy financial burden (9). Furthermore, persistent respiratory symptoms, particularly in young adults, are associated with an accelerated decline in lung function, an increased incidence of obstructive and restrictive physiological conditions and an elevated risk of future lung diseases (10).

Helicobacter pylori (a H. pylori) is a slow-growing, microaerophilic, gram-negative bacterium; its most striking biochemical characteristic is the abundant production of urease. The prevalence of a H. pylori positive state varies from <40% in developed countries to >70% in developing countries (11). a H. pylori positive state is causally associated with various health conditions, including chronic active gastritis, peptic ulcer disease and gastric cancer (12). Over the past few years, a variety of extradigestive disorders, particularly respiratory system diseases, including chronic bronchitis, bronchiectasis, pulmonary tuberculosis, asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), have been reported to be associated with a H. pylori positive state (13,14). In addition, a H. pylori has been detected in the tracheobronchial aspirates of mechanically ventilated patients and the possibility that it may cause ventilator-associated pneumonia has been raised. Furthermore, previous studies have investigated a potential role for a H. pylori positive state in several clinical conditions (15). Their results demonstrated that a H. pylori positive state may be associated with several clinical manifestations (16-18), including chronic persistent cough. However, the exact underlying mechanisms have remained elusive. The current retrospective study was performed to investigate the role of a H. pylori positive state in CC.

 Materials and methods <sec> <title>Patients and selection criteria

A total of 278 adult patients referred to the respiratory clinic of Shaoxing People's Hospital (Shaoxing, China) due to chronic persistent cough over a 2-year enrolment period (June 2016-May 2018), including outpatients and inpatients, were enrolled in the present study. The control group was recruited from the Physical Examination Centre of Shaoxing People's Hospital (Shaoxing, China) and included 148 age- and sex-matched subjects with no history of CC, of whom 87 were females and 61 were males (female/male ratio, 1.4:1), with a mean age of 48.6 years (95% CI: 46.53-50.75). The CC group included 176 females and 102 males (female/male ratio, 1.7:1), with a mean age of 48.2 years (95% CI: 34.86-61.46).

The patients with different types of cough were required to meet the following inclusion and exclusion criteria: i) Τhe major or only clinical symptom is a cough lasting for >8 weeks. ii) No exposure to environmental irritants. iii) Normal or near-normal chest radiographs or chest CT scans (no or minor stable inconsequential scarring). iv) No treatment with angiotensin-converting enzyme inhibitors. v) No response to antibiotic therapy. vi) Exclusion of chronic bronchitis, bronchiectasis, typical asthma, COPD and interstitial lung disease. vii) Exclusion of combination of two or more causes of CC.

 Diagnosis

The diagnostic criteria according to Guidelines for diagnosis and treatment of cough (version 2015) (19) for the different types of cough are described below.

 CRC

Persistent CC despite thorough investigation and conventional treatment according to published practice guidelines.

 CVA

i) CC, usually irritating cough at night. ii) A positive result through bronchial provocation tests or bronchial dilation test or lung function mean diurnal peak expiratory flow (PEF) variation rate index >10% (continuous detection for at least 7 days). iii) Cough improved significantly or even disappeared following anti-asthmatic treatments.

 AC

i) CC, usually irritating dry cough. ii) Normal pulmonary ventilation and a negative result through bronchial provocation tests. iii) Normal numbers of sputum eosinophils. iv) A positive result in detection of atopy or total serum immunoglobulin (Ig) E levels or a history of allergic diseases or exposure to allergenic substances. v) Cough improved significantly or even disappeared after glucocorticoid or anti-histamine treatments.

 UACS

i) Paroxysmal or persistent cough occurring more frequently in the daytime, with disappearance or decrease during sleep. ii) Clinical manifestation and medical history of nasal or pharyngeal diseases. iii) Adjunctive examination supporting the diagnosis of nasal or pharyngeal diseases. iv) Cough improved significantly or even disappeared after treatment of the nasal or pharyngeal diseases.

 GERC

i) CC occurring mainly in the daytime, associated with typical reflux symptoms (e.g. chest pain) or food intake. ii) Symptom index ≥45% or DeMeester score ≥12.7 (24 h ambulatory oesophageal pH monitoring) or symptom association probability ≥80%. iii) Cough improved significantly or even disappeared after anti-reflux therapy.

 EB

i) CC, usually irritating dry cough, or cough with a small amount of phlegm. ii) Normal pulmonary ventilation, no airway hyperresponsiveness and normal lung function mean diurnal PEF variation rate index. iii) Percentage of sputum eosinophils ≥2.5%. iv) Exclusion of other diseases characterised by eosinophil infiltration and proliferation. v) Cough improved significantly or even disappeared after oral or inhaled glucocorticoid treatment.

 Other rare causes

i) Psychogenic cough: a) CC occurring only in the daytime with disappearance during sleep or while focusing on something. b) CC aggravated by a variety of psychological factors. c) A negative result following thorough investigation of CC. d) Exclusion of other causes of CC. e) Cough improved significantly or even disappeared after psychotherapy, anti-anxiety or anti-depressant therapy. ii) Post-infectious cough: a) CC persisting after the disappearance of acute symptoms of respiratory infections, usually irritating dry cough or with a small amount of phlegm. b) Normal or near-normal (no more than stable inconsequential scarring) chest radiographs or chest CT scans; c) Exclusion of other causes of CC; d) Cough improved significantly or even disappeared after anti-tussive, anti-histamine or decongestant treatment.

 Evaluation of cough severity

A self-administered symptom telephone questionnaire was used to evaluate cough severity and its effect on the quality of life on a ranking scale, with scores of 1, 2, 3 and 4 indicating mild, moderate, severe and highly severe complaints with high impairment of life quality, respectively.

Occasional cough was graded as mild (cough symptom score, 1).

Intermittent cough without affecting the quality of life (including the quality of sleep) was graded as moderate (cough symptom score, 2).

Intermittent cough with a mild impairment of life quality (including the quality of sleep) was graded as severe (cough symptom score, 3).

Persistent cough with a serious impairment of life quality (including the quality of sleep) was graded as highly severe (cough symptom score, 4).

 Clinical examination

The medical history of patients with CC frequently provided important initial clues. The history of the patients included in the present study was thoroughly recorded, including meticulous assessment of the symptoms, by using telephone interviews. The concurrent symptoms may suggest a suitable diagnosis. At the Shaoxing People's Hospital, CC is diagnosed strictly according to the diagnostic criteria outlined above. Subsequently, the necessary examinations and experimental treatments may be performed to make an accurate diagnosis and clearly determine the causes of the CC.

Clinical examinations were performed, including chest X-ray or CT, lung function measurements, including the bronchodilatation test or bronchial provocation test, esophagogastroduodenoscopy or 24-h ambulatory oesophageal pH monitoring, nasal endoscopy, laryngoscopy, paranasal sinus X-ray or CT, induced sputum eosinophils, bronchoscopy and detection of atopy, total serum IgE levels, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and eosinophil (EO) count in the peripheral blood. IgE levels >200 IU/ml were considered positive. A a H. pylori positive state was assayed using the 13C or 14C urea exhalation test (01 tester; Shenzhen Zhonghe Headway Biological Technology Co. Ltd.). All the participants were examined on an empty stomach in the morning.

Certain patients with a H. pylori positive state received a bismuth-containing quadruple therapy consisting of amoxicillin (1 g twice daily), clarithromycin (500 mg twice daily) and omeprazole (20 mg twice daily) for 14 days (20). The a H. pylori status was followed up for 6 weeks after the completion of treatments. a H. pylori eradication treatment was offered based on the gastroenterologists' discretion according to the American College of Gastroenterology Clinical Guidelines (version 2017) (21).

 Statistical analysis

SPSS (version 20.0; IBM Corp.) statistical software was used for data analysis. Multivariate analysis was used to investigate the independent association of a H. pylori and CC. Comparisons of log-transformed CRP and ESR values, blood EO count, lung function indices [forced expiratory volume in 1 sec (FEV1), forced vital capacity (FVC), maximal vital capacity (VCmax)] as well as body height, body weight and body mass index (BMI) between groups were performed by an unpaired Student's t-test. The χ2 test was used to compare the prevalence of a H. pylori positive state, symptom improvement rate, atopy, serum IgE levels and other data including sex, age, educational background and smoking status among groups. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Patient characteristics

The present study included a total of 426 subjects, which were divided into two groups. The study group included 278 patients with chronic persistent cough, who were then subdivided into 7 subgroups according to the causes of CC as described above (CC: Cough lasting for >8 weeks in patients who exhibited a normal chest radiograph, are not receiving therapy with angiotensin-converting enzyme inhibitors and have not been exposed to environmental irritants such as occupational dust and chemical substances).

The control group recruited from the Physical Examination Centre of Shaoxing People's Hospital included 148 age- and sex-matched subjects with no history of CC or other respiratory diseases. No significant difference in sex, age, body height, body weight, BMI, educational background or smoking status was present between the CC and control groups (P>0.05). In the CC group, there was also no significant difference in sex, age, height, weight, BMI, educational background and smoking status between a H. pylori positive and negative cases (P>0.05). However, patients with a H. pylori positive (Tables I, II and III).

 H. pylori positivity

The rate of H. pylori positivity was 170/278 (61.2%) in the CC group and 65/148 (43.9%) in the control group. The difference was indicated to be statistically significant (P<0.05). Furthermore, there were 42/61 (68.9%) a H. pylori-positive cases in the CRC group (P<0.05), 69/113 (61.1%) in the CVA group (P<0.05), 16/26 (61.5%) in the AC group (P>0.05), 13/20 (65%) in the UACS group (P>0.05) and 22/37 (59.5%) in the GERC group (P>0.05) compared with the control group. The remaining two groups were not analysed due to insufficient numbers of patients. The results are presented in Table IV.

 Pulmonary function

Patients with CC exposed to a H. pylori exhibited lower lung function as compared with those who were not, with a decrease in FEV1 by 84 ml, a decrease in FVC by 53 ml and a decrease in VCmax by 46 ml (P>0.05). Although the difference did not reach statistical significance, it became statistically significant after adjusting for height, weight, age, sex and ethnicity (the adjusted value was expressed as percent predicted pulmonary function, P<0.05). There was no significant difference in the aforementioned pulmonary function indices between a H. pylori-positive and -negative cases in the control group (P>0.05; Table VI).

Furthermore, a subgroup analysis was performed. Patients in the CRC group exposed to a H. pylori exhibited lower lung function compared with those who were not, with a decrease in FEV1 by 395 ml (P<0.05), a decrease in FVC by 335 ml (P>0.05) and a decrease in VCmax by 314 ml (P>0.05). After adjusting for height, weight, age, sex and ethnicity, effect modification was observed for the association between a H. pylori positive state and pulmonary function in the CRC group (P<0.05). The percent predicted pulmonary function was calculated using a prediction formula according to epidemiological survey data of the East China area from Shanghai Zhongshan Hospital, Fudan University (22). The results are presented in Tables V and VI and Figs. 1 and 2.

 Atopy and total IgE

Patients with CC who were a H. pylori-positive had fewer allergic conditions compared with those who were a H. pylori-negative, as evaluated by determination of atopy and total serum IgE levels (P<0.05). There was no statistically significant association between a H. pylori exposure and allergic conditions in the CVA and AC groups. However, the subgroup analysis according to age revealed an inverse association between a H. pylori positive state and allergic conditions in those patients. The allergic status differed significantly according to age between a H. pylori-positive and -negative cases in the CVA and AC groups. Among the patients aged <40 years, a H. pylori-positive patients had a lower prevalence of atopy compared with a H. pylori-negative cases (46.9 vs. 81.8%, P<0.05). After defining serum IgE levels >200 IU/ml as positives, there was a significantly reduced number of IgE-positive patients in the H. pylori-positive subgroup among patients aged <40 years (37.5 vs. 72.7%, P<0.05). The results are provided in Table VII.

 CRP, ESR and EO in the peripheral blood

There was no significant association between H. pylori status and CRP, ESR or EO count in the peripheral blood following the log-transformation (P>0.05). The results of the subgroup analysis according to the cause of CC were consistent (P>0.05; Data not shown). The results are presented in Table VIII.

 Effect of a H. pylori eradication

Patients with CC exposed to H. pylori had higher cough symptom scores and poorer therapeutic responses (cough symptom score: 2.92±0.93 in H. pylori-positives vs. 2.50±0.92 in H. pylori-negatives; P<0.001). The patients with CRC were followed up. A total of 29 patients with CRC received H. pylori eradication treatment, 19 of whom exhibited an improvement in the cough and the cough-specific quality of life at 1-2 months after successful eradication (improvement was defined as a reduction in the ranking scores of the evaluated symptoms of at least 1). However, a long-term follow-up study is required to fully elucidate the effect of H. pylori eradication on pulmonary function. The results are presented in Table IX.

 Discussion

Since Warren and Marshall (23) reported on the culture of a spiral bacterium from the stomach in 1983, subsequently named a H. pylori, the causative role of this gram-negative bacterium in various upper-gastrointestinal-tract diseases has been increasingly recognized (24,25). With advancing research, several studies focused on the association between a H. pylori positive state and extra digestive diseases, including respiratory system diseases (26,27). It was reported by scholars from Alexandria University that a H. pylori positive state may lead to several clinical manifestations of respiratory-tract diseases (15). Furthermore, a H. pylori has been identified in the tracheobronchial aspirates of mechanically ventilated patients and may cause ventilator-associated pneumonia (28). This prompted us to investigate the possible association between a H. pylori positive state and CC, particularly CRC.

The present study revealed that a high percentage (up to 61.2%) of patients with CC suffered from active a H. pylori infection (29), particularly those with CRC (up to 68.9%). This was significantly higher compared with the percentage of active a H. pylori positive state among controls without cough (43.9%). Subsequently, a follow-up study was performed by telephone interviews. The results revealed that 65.5% (19/29) of patients with CRC who had received a H. pylori eradication treatment exhibited an improvement in their cough and the cough-associated quality of life at 1-2 months after successful eradication. Thus, it may be inferred from the results that there may be a potential association between a H. pylori positive state and CC. The results of the present study are consistent with those reported by a study from the Alexandria University (15).

While the pathogenetic mechanisms underlying the effects of a H. pylori on airway disorders remain to be determined, they may involve chronic inflammation promoted by persistent infection with a H. pylori (30,31). It is well-known that a H. pylori colonization of the gastric mucosa stimulates the release of various pro-inflammatory factors, including cytokines and eicosanoids. The neutrophil-activating protein of a H. pylori is a major pro-inflammatory factor that not only has a key role in driving T-helper type 1 (Th1) inflammation, but is also able to inhibit Th2-mediated bronchial inflammation (32,33). Talaat et al (15) suggested that continuous release of inflammatory mediators by a H. pylori may result in direct or indirect effects on the oesophageal mucosa, which increased its sensitivity to acid and affected the motility of the oesophageal sphincter. As a result, exposure of the lower oesophagus to comparably short-term reflux episodes, through vagally mediated reflexes, may result in persistent cough.

Furthermore, a H. pylori is capable of adhering to epithelial cell lines originally derived from different organs, including respiratory tract epithelial cells. a H. pylori was recently identified in the tracheobronchial aspirates of mechanically ventilated patients and there may be an association between a H. pylori and ventilator-associated pneumonia (28). A study from Japan demonstrated that a H. pylori VacA, the major exotoxin of a H. pylori, was present in the human lung and induced inflammatory factor production by human lung cells (34). It is possible that a H. pylori is aspirated into the respiratory tract from the oropharynx or the gastric reservoir, thereby causing chronic persistent cough. This chronic microaspiration may be involved in chronic inflammatory injuries of the airway epithelia, as well as a systemic immune response that affects the respiratory system in susceptible patients. VacA may exert a local immunosuppressive effect. VacA inhibits the production of interleukin (IL)-2, which is required for T-cell viability and proliferation, and downregulates the surface expression of IL-2 receptor-α (32). In addition, it was reported that VacA induced apoptosis by release of cytochrome c from mitochondria and activation of caspase-3, which may lead to airway injury (35).

A clinical study from the Nottingham City Hospital demonstrated that individuals with a H. pylori positive state exhibited decreased lung function, with FEV1 being lower by 53 ml and FVC by 83 ml in their cross-sectional analysis, although this association was not independent of body height or the socioeconomic status (36). Similar results were reported by a Canadian study, which demonstrated that patients who were seropositive for a H. pylori had lower FEV1 values compared with individuals who were seronegative for a H. pylori; however, the significance of the association between FEV1 and a H. pylori seropositivity disappeared when FEV1 percent predicted values were used (37). Furthermore, previous studies demonstrated that a H. pylori positive state was associated with reduced lung function in patients with COPD and IPF, which is most likely due to the effect of the bacterium on lung growth earlier in life (38,39). Systemic inflammation may also be a contributing factor.

The present study investigated the effect of a H. pylori positive state on lung function, as well as the systemic inflammation as evaluated by CRP, ESR, IgE and peripheral blood EO count in patients with CC. The results demonstrated that patients exposed to a H. pylori in the CC group had a lower percent predicted lung function compared with those who were negative for H. pylori. The difference was even more obvious in the CRC group. Furthermore, there was no association between a H. pylori status and lung function in the control group. Therefore, it may be inferred that in patients with CC, a H. pylori positive state is associated with decreased lung function, although further studies and a long-term follow-up are required to confirm this potential association. However, no significant association was observed between a H. pylori positive state and systemic inflammation markers, including CRP, ESR, IgE and EO count.

Persistent airway injury and inflammation cause airway remodelling and a progressive impairment of lung function, leading to chronic airway diseases. Studies have demonstrated that in young adults, persistent respiratory symptoms, including persistent cough, were associated with an accelerated decline in lung function, incidence of obstructive and restrictive physiology and a higher risk of future radiographic emphysema (10,40). The potential association between a H. pylori positive state and CC indicates that the presence of cough-associated respiratory symptoms and persistent airway inflammation induced by a H. pylori may serve as a prognostic marker for accelerated decline in lung function and future lung diseases. This association was more obvious in patients with CRC.

A meta-analysis demonstrated that a H. pylori positive state was associated with an estimated 18% reduction in the risk of atopy, as estimated by allergen skin tests and specific IgE (41). Whether a H. pylori positive state is inversely associated with allergic diseases remains controversial (42-45). An experimental study demonstrated that oral immunomodulators with a H. pylori extract prevented airway hyperresponsiveness, bronchoalveolar eosinophilia, pulmonary inflammation and Th2 cytokine production, which are hallmarks of allergen-induced asthma, in mice (44). Similar results were also obtained in a recent study (45). Furthermore, several large cross-sectional and case-control studies demonstrated an inverse association between a H. pylori positive state and allergic diseases, including inflammatory airway diseases (44). However, others reported no association or a weak inverse association (41). In the present study, patients with CC who were a H. pylori-positive had fewer allergic conditions compared with those who were a H. pylori-negative, as evaluated by determination of atopy and total serum IgE levels. However, there was no statistically significant association between H. pylori exposure and allergic conditions in the CVA and AC groups. Of note, the subgroup analysis according to age revealed an inverse association between a H. pylori positive state and allergic conditions in those patients. Among those aged <40 years, a H. pylori-positive patients had a lower prevalence of atopy and serum IgE levels compared with a H. pylori-negative cases. The present results were in line with Korean studies, according to which the association of IgE hypersensitivity and allergic diseases with a H. pylori positive state differed depending on age (44,46). Another study observed that early exposure to H. pylori was inversely associated with allergic conditions, which was possibly linked to infection with CagA+ strains of H. pylori (41).

The gradual loss of the human indigenous microbiota may be implicated in the increasing trend in the prevalence of allergic diseases (42). H. pylori, as a bacterial pathogen, is a constituent of the normal gastric microbiota, which may partly explain the inverse association between a H. pylori positive state and allergic conditions in patients with CVA and AC aged <40 years (42). According to the ‘decreasing microbiota hypothesis’, the intestinal microbiota affects the immune system and commensal bacteria regulate the Th1/Th2 equilibrium. H. pylori, an ancient indigenous microbe, is expected to affect the immune system by shifting the cytokine balance toward the Th1 type, which suppresses Th2-dominated allergic diseases. It has been reported that H. pylori alters the T-cell response by inducing the expression of IL-12, tumour necrosis factor-α and interferon-γ by T-cells. In the present study, an inverse association between H. pylori and allergic conditions in patients with CVA and AC aged <40 years, but not in those aged >40 years was identified. The reason for this remains elusive; however, it may be associated with the pathophysiological processes of CVA and AC, which also require further study. In addition, this is complicated by the fact that certain children may change back from a positive to a negative status of H. pylori positivity. In a population-based birth cohort in Ethiopia, 17% of children with evidence of a H. pylori positive state at the age of 3 years ceased to be negative at the age of 5 years (47). The issue of the fluctuating exposure status remains a major challenge.

Patients with chronic persistent cough experience a significant reduction in their quality of life, particularly patients with refractory chronic persistent cough. Persistent cough in young adults was associated with accelerated decline in lung function, which was associated with a greater risk of future development of lung diseases, including COPD. Therefore, it is crucial to develop an effective treatment. The present study raised the possibility that H. pylori may be a cause of chronic cough, and that eradication of this pathogen may resemble a potential treatment. In certain patients with CRC, including those with unexplained chronic cough, the symptoms subsided after a successful H. pylori eradication, which may prevent the decline in lung function and airway remodelling. In addition, a vaccination for preventing or treating a H. pylori infection may be of value, particularly during childhood. Since a recent mouse study demonstrated that the protective effect of H. pylori against allergic diseases did not require live bacteria, treatment with an extract of H. pylori in neonates may prevent the development of airway allergic diseases (48,49). The application of H. pylori extract, particularly in early life, may be an effective prevention and treatment measure for CVA and AC (43). Of note, the present study had certain limitations. A larger sample size and multicentre prospective clinical trials are required to verify the effectiveness of this novel potential clinical therapeutic strategy.

In conclusion, the results of the present study support the theory of a potential association between a H. pylori positive state and CC, including CRC, CVA and AC. In addition, HPI may be associated with the accelerated decline of lung function in patients with chronic persistent cough, which may lead to irreversible airway remodelling and even the future development of chronic airway diseases. However, there is an inverse association between HPI and allergic diseases, including CVA and AC. Thus, H. pylori may be a promising target for the treatment of chronic persistent cough. However, further research is required.

 Acknowledgements

Not applicable.

 Funding

This work was supported by grants from Department of Health of Zhejiang Province, China (grant no. 2019KY226) and Shaoxing Bureau of Science and Technology, Zhejiang Province, China (grant no. 2018C30097). It was also supported by Zhejiang Provincial Natural Science Foundation of China under Grant No. LQ20H010001.

 Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

MH and KT designed the research and did most of the work. JS was mainly responsible for the interpretation of data, and also revised it critically for the important intellectual content. AM and YZ were mainly responsible for the acquisition and analysis of data. CZ, YY and HW were mainly accountable for ensuring the questions related to the accuracy or integrity of the work to be appropriately investigated and resolved, and performed the experiments. YC and MX also performed some of the experiments. All the authors read and approved the final manuscript.

 Ethics approval and consent to participate

This article does not contain any prospective studies with human participants or animals performed by any of the authors. It was approved by leaders of Shaoxing People's Hospital and registered and approved by the ethics committee of Shaoxing People's Hospital (Shaixing, China). Informed consent was obtained from all individual participants included in the study by telephone interviews.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References SmithJAWoodcockAChronic coughN Engl J Med37618318420172807671810.1056/NEJMc1615067 ChungKFIFN-γ: A driver of cough hypersensitivity pathways in chronic coughAm J Respir Crit Care Med19882782820182975816510.1164/rccm.201804-0740ED HerregodsTVKPauwelsAJafariJSifrimDBredenoordAJTackJSmoutAJPMDeterminants of Reflux-induced chronic coughGut662057206220172829835410.1136/gutjnl-2017-313721 SongWJKimHJShimJSWonHKKangSYSohnKHKimBKJoEJKimMHKimSHDiagnostic accuracy of fractional exhaled nitric oxide measurement in predicting cough-variant asthma and eosinophilic bronchitis in adults with chronic cough: A systematic review and meta-analysisJ Allergy Clin Immunol14070170920172808847410.1016/j.jaci.2016.11.037 GibsonPWangGMcGarveyLVertiganAEAltmanKWBirringSSTreatment of Unexplained Chronic Cough: CHEST guideline and expert panel reportChest149274420162642631410.1378/chest.15-1496 MillqvistEThe problem of treating unexplained chronic coughChest14961361420162696596310.1016/j.chest.2015.12.008 AbdulqawiRDockryRHoltKLaytonGMcCarthyBGFordAPSmithJAP2X3 receptor antagonist (AF-219) in refractory chronic cough: A randomised, Double-blind, Placebo-controlled phase 2 studyLancet3851198120520152546758610.1016/S0140-6736(14)61255-1 GopalAKSchusterSJFowlerNHTrotmanJHessGHouJZYacoubALillMMartinPVitoloUIbrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN studyJ Clin Oncol362405241220182985154610.1200/JCO.2017.76.8853 SmithJAHainesJYorkeJTaming chronic coughThorax7210310420172782172210.1136/thoraxjnl-2016-209484 KalhanRDransfieldMTColangeloLACutticaMJJacobsDR JrThyagarajanBEsteparRSJHarmoucheROnievaJOAshSYRespiratory symptoms in young adults and future lung disease The CARDIA lung studyAm J Respir Crit Care Med1971616162420182936968410.1164/rccm.201710-2108OC ChoiIJKimYIParkBHelicobacter pylori and prevention of gastric cancerN Engl J Med3782244224520182956214710.1056/NEJMoa1708423 AbbasiJBarry marshall and MD: H pylori 35 Years LaterJAMA3171400140220172839925010.1001/jama.2017.2629 EhrlichDNainiBMukewarSA rare cause of gastric wall thickeningGastroenterology154e18e2020182898906410.1053/j.gastro.2017.09.040 KochKNHartungMLUrbanSKyburzABahlmannASLindJBackertSTaubeCMüllerAHelicobacter urease-induced activation of the TLR2/NLRP3/IL-18 Axis protects against asthmaJ Clin Invest125329730220152621452410.1172/JCI79337 TalaatMGadMSMagdyEAAggagSMNourYAHelicobacter pylori infection and chronic, persistent cough: Is there an associationJ Laryngol Otol121962720071729593310.1017/S0022215107005671 WangLGuanYLiYLiuXZhangYWangFKongLGuoQAssociation between chronic respiratory diseases and Helicobacter pylori: A meta-analysisArch Bronconeumol5127327820152579727610.3109/00365548.2014.989539 KreuterMKirstenDBahmerTPenzelRClaussenMEhlers-TenenbaumSMuleyTPalmowskiKEichingerMLeiderMScreening for Helicobacter pylori in idiopathic pulmonary fibrosis lung biopsiesRespiration913820162664521310.1159/000442449 HongLLiSFengQFengXJinYZhaoQZhangHH. pylori infection may cause sleep-related laryngospasm for a patient in climactericJ Pain Symptom Manage39e6e720102053817910.1016/j.jpainsymman.2010.02.002 KefangLaiGuidelines for diagnosis and treatment of cough (2015). Chinese Journal of Tuberculosis and Respiratory Diseases: 323-354, 2016. LiouJMFangYJChenCCBairMJChangCYLeeYCChenMJChenCCTsengCHHsuYCConcomitant, bismuth quadruple, and 14-day triple therapy in the First-line treatment of Helicobacter pylori: A multicentre, Open-label, randomised trialLancet3882355236520162776956210.1016/S0140-6736(16)31409-X CheyWDLeontiadisGIHowdenCWMossSFACG Clinical Guideline: Treatment of Helicobacter pylori InfectionAm J Gastroenterol11221223920172807165910.1038/ajg.2016.563 ZhaoRYZhuLLiLChenQYangYJThe applicability of the 1988 version of the prediction equations for adult normal lung function in ShanghaiZhonghua Jie He He Hu Xi Za Zhi34586589201122168980(In Chinese) ParsonnetJClinician-discoverers-Marshall, Warren, and H. pyloriN Engl J Med353242124232005 LanasAChanFKLPeptic ulcer diseaseLancet39061362420172824211010.1016/S0140-6736(16)32404-7 KimIJLeeJOhSJYoonMSJangSSHollandRLRenoMLHamadMNMaedaTChungHJHelicobacter pylori Infection modulates host cell metabolism through VacA-dependent inhibition of mTORC1Cell Host Microbe23583593.e820182974683110.1016/j.chom.2018.04.006 KariyaSOkanoMNishizakiKAn Association between Helicobacter pylori and upper respiratory tract disease: Fact or fictionWorld J Gastroenterol201470148420142458762210.3748/wjg.v20.i6.1470 De KorwinJDIaniroGGibiinoGGasbarriniAHelicobacter pylori infection and extragastric diseases in 2017. Helicobacter: 22 (Suppl 1), 2017 doi: 10.1111/hel.12411. GülhanMOzyilmazETarhanGDemirağFCapanNErtürkACanbakanSAyaşlioğluEGülhanEAhmedKHelicobacter pylori in bronchiectasis: A polymerase chain reaction assay in bronchoalveolar lavage fluid and bronchiectatic lung tissueArch Med Res3831732120071735048210.1016/j.arcmed.2006.11.010 El-SeragHBKaoJYKanwalFGilgerMLoVecchioFMossSFCroweSEElfantAHaasTHapkeRJGrahamDYHouston consensus conference on testing for Helicobacter pylori Infection in the United statesclin gastroenterol hepatol169921002.e620182955936110.1016/j.cgh.2018.03.013 RossiAFCadamuroACBiselli-PericoJMLeiteKRSeverinoFEReisPPCordeiroJASilvaAEInteraction between inflammatory mediators and miRNAs in Helicobacter pylori InfectionCell Microbiol181444145820162694569310.1111/cmi.12587 BarrozoRMHansenLMLamAMSkoogECMartinMECaiLPLinYLatoschaASuerbaumSCanfieldDRCagY is an Immune-sensitive regulator of the Helicobacter pylori type iv secretion systemGastroenterology15111641175.e320162756972410.1053/j.gastro.2016.08.014 D'EliosMMMontecuccoCde BernardMVacA and HP-NAP, Ying and Yang of Helicobacter pylori-associated gastric inflammationClin Chim Acta381323820071736844110.1016/j.cca.2007.02.026 RamachandranMJinCYuDErikssonFEssandMVector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and Improved MigrationJ Immunol1932287229620142504935810.4049/jimmunol.1400339 NakashimaSKakugawaTYuraHTomonagaMHaradaTHaraAHaraSNakanoMYamasakiESakamotoNIdentification of Helicobacter pylori vaca in human lung and its effects on lung cellsBiochem Biophys Res Commun46072172620152581779510.1016/j.bbrc.2015.03.096 MontecuccoCde BernardMImmunosuppressive and proinflammatory activities of the VacA Toxin of Helicobacter pyloriJ Exp Med1981767177120031467629110.1084/jem.20031839 FullertonDBrittonJRLewisSAPavordIDMcKeeverTMFogartyAWHelicobacter pylori and lung function, asthma, atopy and allergic disease-a population-based cross-sectional study in adultsInt J Epidemiol3841942620091910924810.1093/ije/dyn348 GencerMCeylanEYildizZFAksoyNHelicobacter pylori seroprevalence in patients with chronic obstructive pulmonary disease and its relation to pulmonary function testsRespiration7417017520071636912110.1159/000090158 SzeMAChenYWTamSTashkinDWiseRAConnettJEManSPSinDDThe relationship between Helicobacter pylori Seropositivity and COPDThorax7092392920152602468810.1136/thoraxjnl-2015-207059 FogartyAWDoes Helicobacter pylori Infection modify lung development, height or simply reflect shared environmental exposuresThorax7091820152612365810.1136/thoraxjnl-2015-207270 WangCXuJYangLXuYZhangXBaiCKangJRanPShenHWenFChina pulmonary health study group Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): A national Cross-sectional studyLancet3911706171720182965024810.1016/S0140-6736(18)30841-9 TayeBEnquselassieFTsegayeAAmberbirAMedhinGFogartyARobinsonKDaveyGAssociation between infection with Helicobacter pylori and atopy in young ethiopian children: A longitudinal studyClin Exp Allergy471299130820172878777110.1111/cea.12995 EnglerDBReuterSvan WijckYUrbanSKyburzAMaxeinerJMartinHYogevNWaismanAGerhardMEffective treatment of allergic airway inflammation with Helicobacter pylori immunomodulators requires BATF3-dependent dendritic cells and IL-10Proc Natl Acad Sci USA111118101181520142507491710.1073/pnas.1410579111 van WijckYde KleijnSJohn-SchusterGMertensTCJHiemstraPSMüllerASmitsHHTaubeCTherapeutic application of an extract of Helicobacter pylori ameliorates the development of allergic airway diseaseJ Immunol2001570157920182935200410.4049/jimmunol.1700987 LimJHKimNLimSHKwonJWShinCMChangYSKimJSJungHCChoSHInverse relationship between Helicobacter pylori infection and asthma among adults younger than 40 years: A cross-sectional studyMedicine (Baltimore)95e260920162693789910.1097/MD.0000000000002609 van WijckYJohn-SchusterGvan SchadewijkAvan den OeverRLObiegloKHiemstraPSMüllerASmitsHHTaubeCExtract of Helicobacter pylori ameliorates parameters of airway inflammation and goblet cell hyperplasia following repeated allergen exposureInt Arch Allergy Immunol1801920193124249310.1159/000500598 LeeSPLeeSYKimJHSungIKParkHSShimCSMoonHWCorrelation between Helicobacter pylori Infection, IgE hypersensitivity, and allergic disease in korean adultsHelicobacter20495520152525709910.1111/hel.12173 AmberbirAMedhinGAbegazWEHanlonCRobinsonKFogartyABrittonJVennADaveyGExposure to Helicobacter pylori infection in early childhood and the risk of allergic disease and atopic sensitization: A longitudinal birth cohort studyClin Exp Allergy4456357120142452837110.1111/cea.12289 LeppoldCTanimotoTOzakiAMoritaTSariPVHelicobacter pylori VaccinationLancet38774874920162690666410.1016/S0140-6736(16)00328-7 LiuHLiuWTanZZengZYangHLuoSWangLXiTXingYPromoting immune efficacy of the oral Helicobacter pylori Vaccine by HP55/PBCA nanoparticles against the gastrointestinal environmentMol Pharm153177318620183001121310.1021/acs.molpharmaceut.8b00251

Predicted pulmonary function in the CC group. CC patients with a H. pylori positive had lower lung function than those who were not after adjusting for factors including height, weight, age, sex and ethnicity. The adjusted value was expressed as percent predicted pulmonary function. Values: *P<0.001 and #P<0.05 vs. negative group. FEV1, forced expiratory volume in 1 sec; FVC, forced vital capacity; VCmax, maximal vital capacity.

Predicted pulmonary function in the chronic refractory cough group. Patients in the chronic refractory cough group exposed to a H. pylori had lower lung function than those who were not after adjusting for factors including height, weight, age, sex and ethnicity. The adjusted value was expressed as percent predicted pulmonary function. Values: A, 102.24±8.3 (P<0.001); B, 115.23±10.8; C, 106.06±10.6 (P=0.002); D, 115.82±10.8; E, 106.51±10.4 (P=0.003); F, 115.62±10.9. *P<0.001 and #P<0.05 vs. negative group. FEV1, forced expiratory volume in 1 sec; FVC, forced vital capacity; VCmax, maximal vital capacity.

Patient characteristics.

Characteristics CC group (n=278) Control group (n=148) P-value
Sex, female/male 176/102 87/61 0.36
Age, years 48.16±13.30 48.64±13.00 0.289
Body height, cm 162.91±7.63 162.85±7.27 0.942
Body weight, kg 62.38±9.92 59.88±11.00 0.018
BMI, kg/m2 23.44±2.86 22.48±3.19 0.22
Education, years 9.80±4.20 10.21±3.72 0.517
Smoking      
Pack years 2.73±8.12 4.43±11.06 0.089
Time since smoking cessation, years 0.24±1.60 0.21±1.24 0.502

Continuous variables are expressed as the mean ± standard deviation. BMI, body mass index.

CC patient characteristics.

Variable H. pylori positive H. pylori negative P-value
Number 170 108  
Sex (male/female) 68/102 34/74 0.15
Age 46.54±12.42 50.71±14.27 0.07
Heigh (cm) 163.45±7.54 162.06±7.71 0.14
Weight (Kg) 62.53±10.60 62.13±8.80 0.74
BMI 23.31±2.95 23.64±2.73 0.35
Education (Years) 9.49±4.38 10.27±3.83 0.06
Smoking status Pack years 2.87±8.03 2.51±8.30 0.25

Continuous data are shown as mean ± standard deviation.

Control group patient characteristics.

Variable H. pylori positive H. pylori negative P-value
Number 65 83  
Sex (male/female) 30/35 31/52 0.28
Age 48.45±13.67 48.80±12.54 0.84
Heigh (cm) 163.06±7.36 162.69±7.23 0.76
Weight (Kg) 58.69±9.98 60.81±11.71 0.25
BMI 22.01±2.93 22.86±3.35 0.11
Education(years) 9.12±3.75 11.11±3.36 0.02
Smoking status Pack years 5.61±12.05 3.50±10.20 0.06

Continuous data are shown as mean ± standard deviation.

Prevalence of H. pylori positivity.

Group H. pylori (+), n/totals (%) H. pylori (-), n/totals (%) P-value
CC 170/278 (61.2) 108/278 (38.8) 0.001
CRC 42/61 (68.9) 19/61 (31.1) 0.001
CVA 69/113 (61.1) 44/113 (38.9) 0.006
AC 16/26 (61.5) 10/26 (38.5) 0.097
UACS 13/20 (65.0) 7/20 (35.0) 0.076
GERC 22/37 (59.5) 15/37 (40.5) 0.09
EB 5/11 (45.5) 6/11 (54.5) 0.921
Other rare reasons 5/10 (50.0) 5/10 (50.0) 0.708
Control 65/148 (43.9) 83/148 (56.1)  

CC, chronic cough group; CRC, chronic refractory cough group; CVA, cough variant asthma group; AC, allergic cough group; UACS, upper airway cough syndrome group; GERC, gastroesophageal reflux-associated cough group; EB, eosinophilic bronchitis.

Predicted pulmonary function (%).

  FEV1 FVC VCmax
Group H. pylori (+) H. pylori (-) H. pylori (+) H. pylori (-) H. pylori (+) H. pylori (-)
CC 100.79±14.80a 107.32±15.56 104.78±14.85a 109.00±15.48 105.41±14.30a 109.00±14.50
CRC 102.24±8.33a 115.23±10.82 106.06±10.65a 115.82±10.81 106.51±10.45a 115.62±10.87
CVA 96.15±15.02 101.05±16.26 101.85±14.39 104.52±15.96 102.37±14.05 104.61±14.40
AC 106.11±18.73 108.41±15.62 106.00±21.00 106.50±13.66 107.32±18.93 107.42±14.05
UACS 98.01±13.10a 112.19±11.32 103.68±16.93 114.30±15.83 102.48±17.18 112.06±14.48
GERC 110.58±15.32 109.12±13.68 111.94±15.40 110.15±17.97 113.74±13.74 109.61±17.76
Control 105.80±12.10 107.58±16.28 107.18±15.36 109.46±16.09 107.69±13.88 108.78±15.76

aP<0.05. Values are expressed as the mean ± standard deviation. CC, chronic cough group; CRC, chronic refractory cough group; CVA, cough variant asthma group; AC, allergic cough group; UACS, upper airway cough syndrome group; GERC, gastroesophageal reflux-associated cough group; EB, eosinophilic bronchitis; FEV1, forced expiratory volume in 1 sec; FVC, forced vital capacity; VCmax, maximal vital capacity.

Pulmonary function.

  FEV1, l FVC, l VCmax, l
Group H. pylori (+) H. pylori (-) H. pylori (+) H. pylori (-) H. pylori (+) H. pylori (-)
CC 2.85±0.74 2.93±0.84 3.59±0.89 3.65±0.99 3.70±0.91 3.75±0.99
CRC 2.98±0.61a 3.37±0.85 3.74±0.69 4.08±1.04 3.86±0.72 4.17±1.01
CVA 2.62±0.71 2.80±0.90 3.37±0.85 3.56±1.04 3.46±0.86 3.68±1.06
AC 2.92±0.58 2.82±0.86 3.59±0.89 3.40±1.09 3.74±0.86 3.51±1.08
UACS 2.91±0.91 2.89±0.71 3.69±1.12 3.59±0.90 3.76±1.18 3.61±0.88
GERC 3.25±0.86 2.97±0.75 4.04±1.03 3.66±0.96 4.20±1.03 3.73±0.99
Control 2.94±0.69 2.92±0.78 3.63±0.85 3.63±0.95 3.75±0.87 3.71±0.96

Values are expressed as the mean ± standard deviation.

aP=0.044 vs. H. pylori (-). CC, chronic cough group; CRC, chronic refractory cough group; CVA, cough variant asthma group; AC, allergic cough group; UACS, upper airway cough syndrome group; GERC, gastroesophageal reflux-associated cough group; EB, eosinophilic bronchitis; FEV1, forced expiratory volume in 1 sec; FVC, forced vital capacity; VCmax, maximal vital capacity.

Association between H. pylori exposure and allergic conditions.

Groups Atopy (+), n/total (%) P-value IgE, n/total (%) P-value
Chronic cough        
     H. pylori (+) 46/170 (27.1) <0.05 46/170 (27.1) <0.05
     HP (-) 43/108 (39.8)   44/108 (40.7)  
CVA and AC        
     H. pylori (+) 60/88 (68.2) >0.05 44/88 (50.0) >0.05
     H. pylori (-) 35/53 (66.0)   33/53 (62.3)  
Age <40 years (CVA and AC)        
     H. pylori (+) 15/32 (46.9) <0.05 12/32 (37.5) <0.05
     H. pylori (-) 9/11 (81.8)   8/11 (72.7)  
Control group        
     H. pylori (+) 9/65 (13.8) >0.05 4/65 (6.2) >0.05
     H. pylori (-) 9/83 (10.8)   6/83 (7.2)  

CVA, cough variant asthma group; AC, allergic cough group.

Association between H. pylori exposure and systemic inflammation.

Group H. pylori (+), n (%) H. pylori (-), n (%) P-value
Chronic cough      
     CRP 2.24±6.54 3.43±10.68 0.309
     Log CRP -0.01±0.46 0.03±0.51 0.511
     ESR 10.35±8.31 11.78±13.42 0.419
     Log ESR 0.88±0.36 0.88±0.40 0.943
     EO 0.16±0.18 0.16±0.32 0.914
     Log EO -0.94±0.36 -1.01±0.40 0.175
Control group      
     CRP 4.58±11.19 3.02±6.23 0.316
     Log CRP 0.13±0.66 0.05±0.60 0.486
     ESR 13.68±24.04 13.91±18.10 0.962
     Log ESR 0.88±0.30 0.88±0.35 0.996
     EO 0.13±0.11 0.11±0.10 0.326
     Log EO -1.02±0.38 -1.10±0.41 0.263

Values are expressed as the mean ± standard deviation. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; EO, eosinophil count in peripheral blood.

Cough symptom score in chronic cough and CRC groups (a H. pylori positive vs. a H. pylori negative).

Group H. pylori positive H. pylori negative P-value
Cough symptom score      
     Chronic cough 2.92±0.93 2.50±0.92 P<0.001
     CRC 3.19±0.86 2.26±0.87 P<0.001

Continuous data are shown as mean ± standard deviation. Cough symptom score ranges from 1-4 (1: Mild; 2: Moderate; 3: Severe; 4: Extremely serious).